Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
© The Author(s) 2020..
We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectively. We used a semi-automated Pseudovirion-Based Neutralization Assay and observed significantly higher HPV16/18 peak ab-levels in bivalent as compared to quadrivalent vaccine recipients. Bivalent vaccine induced cross-neutralizing HPV31/33/45/52/58 antibodies significantly more frequently and to higher levels than the quadrivalent vaccine. The correlation of bivalent vaccine-induced HPV45 ab-levels with HPV16/18 ab-levels was stronger than that of corresponding quadrivalent vaccine-induced ab-levels, suggesting a qualitatively different cross-reactive response. Our findings on the comparison of the immunogenicity of two HPV vaccine tested in two different populations indicate that further head-to-head studies are warranted.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:5 |
|---|---|
| Enthalten in: |
NPJ vaccines - 5(2020), 1 vom: 01., Seite 14 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mariz, Filipe Colaço [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 24.03.2024 published: Electronic-eCollection Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1038/s41541-020-0165-x |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM307195937 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM307195937 | ||
| 003 | DE-627 | ||
| 005 | 20240324234413.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41541-020-0165-x |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1344.xml |
| 035 | |a (DE-627)NLM307195937 | ||
| 035 | |a (NLM)32128255 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Mariz, Filipe Colaço |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 24.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2020. | ||
| 520 | |a We performed an independent comparison of neutralizing and cross-neutralizing antibody (ab) levels seven months after initiation of three-dose, six-month vaccination schedules with the bivalent and quadrivalent human papillomavirus (HPV) vaccines in adolescent Finnish and Indian females, respectively. We used a semi-automated Pseudovirion-Based Neutralization Assay and observed significantly higher HPV16/18 peak ab-levels in bivalent as compared to quadrivalent vaccine recipients. Bivalent vaccine induced cross-neutralizing HPV31/33/45/52/58 antibodies significantly more frequently and to higher levels than the quadrivalent vaccine. The correlation of bivalent vaccine-induced HPV45 ab-levels with HPV16/18 ab-levels was stronger than that of corresponding quadrivalent vaccine-induced ab-levels, suggesting a qualitatively different cross-reactive response. Our findings on the comparison of the immunogenicity of two HPV vaccine tested in two different populations indicate that further head-to-head studies are warranted | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cervical cancer | |
| 650 | 4 | |a Viral infection | |
| 700 | 1 | |a Bender, Noemi |e verfasserin |4 aut | |
| 700 | 1 | |a Anantharaman, Devasena |e verfasserin |4 aut | |
| 700 | 1 | |a Basu, Partha |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatla, Neerja |e verfasserin |4 aut | |
| 700 | 1 | |a Pillai, Madhavan Radhakrisna |e verfasserin |4 aut | |
| 700 | 1 | |a Prabhu, Priya R |e verfasserin |4 aut | |
| 700 | 1 | |a Sankaranarayanan, Rengaswamy |e verfasserin |4 aut | |
| 700 | 1 | |a Eriksson, Tiina |e verfasserin |4 aut | |
| 700 | 1 | |a Pawlita, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Prager, Kristina |e verfasserin |4 aut | |
| 700 | 1 | |a Sehr, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Waterboer, Tim |e verfasserin |4 aut | |
| 700 | 1 | |a Müller, Martin |e verfasserin |4 aut | |
| 700 | 1 | |a Lehtinen, Matti |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t NPJ vaccines |d 2016 |g 5(2020), 1 vom: 01., Seite 14 |w (DE-627)NLM273825623 |x 2059-0105 |7 nnns |
| 773 | 1 | 8 | |g volume:5 |g year:2020 |g number:1 |g day:01 |g pages:14 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41541-020-0165-x |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 5 |j 2020 |e 1 |b 01 |h 14 | ||